The genetic basis for inactivation of Wnt pathway in human osteosarcoma

被引:47
|
作者
Du, Xiaoling [1 ,2 ,4 ]
Yang, Jilong [2 ,3 ]
Yang, Da [3 ]
Tian, Wei [2 ]
Zhu, Ze [4 ]
机构
[1] Tianjin Med Univ, Dept Diagnost, Tianjin 300060, Peoples R China
[2] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Bone & Soft Tissue Tumors, Tianjin 30060, Peoples R China
[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[4] Tianjin Med Univ, Dept Med Microbiol, Tianjin 300060, Peoples R China
来源
BMC CANCER | 2014年 / 14卷
关键词
Osteosarcoma; Wnt signal pathway; Genetic aberration; Microarray-based comparative genomic hybridization; BETA-CATENIN; STEM-CELLS; TRANSCRIPTOMES; CHEMOTHERAPY; EXPRESSION; INHIBITOR; DELETIONS; THERAPY; BONE;
D O I
10.1186/1471-2407-14-450
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Osteosarcoma is a highly genetically unstable tumor with poor prognosis. We performed microarray-based comparative genomic hybridization (aCGH), transcriptome sequencing (RNA-seq), and pathway analysis to gain a systemic view of the pathway alterations of osteosarcoma. Methods: aCGH experiments were carried out on 10 fresh osteosarcoma samples. The output data (Gene Expression Omnibus Series accession number GSE19180) were pooled with published aCGH raw data (GSE9654) to determine recurrent copy number changes. These were analyzed using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to identify altered pathways in osteosarcoma. Transcriptome sequencing of six osteosarcomas was performed to detect the expression profile of Wnt signaling pathway genes. Protein expression of WNT1, beta-catenin, c-myc, and cyclin D1 in the Wnt pathway was detected by immunohistochemistry (IHC) in an independent group of 46 osteosarcoma samples. Results: KEGG pathway analysis identified frequent deletions of Wnt and other Wnt signaling pathway genes. At the mRNA level, transcriptome sequencing found reduced levels of mRNA expression of Wnt signaling pathway transcripts. While WNT1 protein expression was detected by IHC in 69.6% (32/46) of the osteosarcomas, no beta-catenin protein was detected in the nucleus. beta-catenin protein expression was, however, detected in the membrane and cytoplasm of 69.6% (32/46) of the osteosarcomas. c-myc protein expression was detected in only 47.8% (22/46) and cyclin D1 protein expression in 52.2% (24/46) of osteosarcoma samples. Kaplan-Meier survival analysis showed that WNT1-negative patients had a trend towards longer disease free survival than WNT1-positive patients. Interestingly, in WNT1-negative patients, those who were also cyclin D1-negative had significantly longer disease free survival than cyclin D1-positive patients. However, there was no significant association between any of the investigated proteins and overall survival of human osteosarcoma patients. Conclusions: Frequent deletions of Wnt and other Wnt signaling pathway genes suggest that the Wnt signaling pathway is genetically inactivated in human osteosarcoma.
引用
收藏
页数:10
相关论文
共 50 条
  • [11] Fibulin-4 is a novel Wnt/β-Catenin pathway activator in human osteosarcoma
    Li, Renzeng
    Wang, Limin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 474 (04) : 730 - 735
  • [12] The Wnt signaling pathway: implications for therapy in osteosarcoma
    McQueen, Peter
    Ghaffar, Samia
    Guo, Yi
    Rubin, Elyssa M.
    Zi, Xiaolin
    Hoangn, Bang H.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (08) : 1223 - 1232
  • [13] Knockdown of HOXB8 inhibits tumor growth and metastasis by the inactivation of Wnt/β-catenin signaling pathway in osteosarcoma
    Guo, Jiankuo
    Zhang, Tianlun
    Dou, Dongmei
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 854 : 22 - 27
  • [14] The canonical Wnt-beta-catenin pathway in development and chemotherapy of osteosarcoma
    Li, Chengjun
    Shi, Xin
    Zhou, Guangxin
    Liu, Xiaozhou
    Wu, Sujia
    Zhao, Jianning
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2013, 18 : 1385 - 1392
  • [15] WNT pathway in oral cancer: Epigenetic inactivation of WNT-inhibitors
    Pannone, G.
    Bufo, P.
    Santoro, A.
    Franco, R.
    Aquino, G.
    Longo, F.
    Botti, G.
    Serpico, R.
    Cafarelli, B.
    Abbruzzese, A.
    Caraglia, M.
    Papagerakis, S.
    Lo Muzio, L.
    ONCOLOGY REPORTS, 2010, 24 (04) : 1035 - 1041
  • [16] Carvacrol Suppresses Human Osteosarcoma Cells via the Wnt/β-Catenin Signaling Pathway
    Zhang, Songou
    He, Lei
    Shang, Jinxiang
    Chen, Long
    Xu, Yifan
    Chen, Xiaozhen
    Li, Xinyu
    Jiao, Qingchuan
    Jin, Songtao
    Hu, Xujun
    Liang, Wenqing
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (09) : 1714 - 1722
  • [17] RETRACTED: Suppression of adriamycin resistance in osteosarcoma by blocking Wnt/β-catenin signal pathway (Retracted Article)
    Wu, B. -Q.
    Cao, Y.
    Bi, Z. -G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (14) : 3185 - 3192
  • [18] Wnt/β-catenin signaling pathway: an attractive potential therapeutic target in osteosarcoma
    Ding, Yi
    Chen, Qin
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [19] Ganoderma lucidum Exerts an Anticancer Effect on Human Osteosarcoma Cells via Suppressing the Wnt/β-Catenin Signaling Pathway
    Zhang, Qi-Hao
    Hu, Qin-Xiao
    Xie, Da
    Chang, Bo
    Miao, Hou-Guang
    Wang, Yun-Guo
    Liu, De-Zhong
    Li, Xue-Dong
    INTEGRATIVE CANCER THERAPIES, 2019, 18
  • [20] Bone morphogenetic protein 9 regulates tumor growth of osteosarcoma cells through the Wnt/β- catenin pathway
    Lv, Zilan
    Wang, Chuan
    Yuan, Taixian
    Liu, Yuehong
    Song, Tao
    Liu, Yueliang
    Chen, Chu
    Yang, Min
    Tang, Zuchuan
    Shi, Qiong
    Weng, Yaguang
    ONCOLOGY REPORTS, 2014, 31 (02) : 989 - 994